GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars
Five things for pharma marketers to know: Tuesday, December 22, 2015
Valeant says it lost few reps despite business scrutiny; Novartis CEO says drugmakers must share benefits of new medicines with other healthcare stakeholders; Bloomberg analysis finds US pays more for branded drugs after discounts
An award-winning campaign about talking fish; the OTC switch for GlaxoSmithKline’s Flonase; a direct-to-consumer push for Afrezza, Sanofi’s and MannKind’s inhaled insulin
Medical association and ad platform partner for in-meeting messaging
Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices
Healthcare industry says it struggles to define value
Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer